Tamoxifen
- Generic Name
- Tamoxifen
- Brand Names
- Soltamox
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29NO
- CAS Number
- 10540-29-1
- Unique Ingredient Identifier
- 094ZI81Y45
- Background
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, s...
- Indication
Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.
- Associated Conditions
- Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
- Associated Therapies
- Ovulation induction therapy
Tamoxifen-MRI Study
- Conditions
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2007-06-21
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 78
- Registration Number
- NCT00295100
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Wayne State University, Detroit, Michigan, United States
🇮🇹European Institute of Oncology, Milan, Italy
Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- International Breast Cancer Research Foundation
- Target Recruit Count
- 249
- Registration Number
- NCT00293540
- Locations
- 🇨🇳
National Railroad, Beijing, China
🇵🇭East Avenue Medical Center, Manila, Philippines
🇵🇭Vicente Sotto Hospital, Manila, Philippines
ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.
- Conditions
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2013-01-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3858
- Registration Number
- NCT00291759
- Locations
- 🇦🇹
Research Site, Zams, Austria
🇦🇹Research Sites, Vienna, Austria
🇦🇹Research SIte, Melk, Austria
Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ
- Conditions
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 45
- Registration Number
- NCT00290654
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2009-06-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1059
- Registration Number
- NCT00287534
- Locations
- 🇩🇪
Research Site, Wuerzburg, Germany
ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years
- First Posted Date
- 2006-02-03
- Last Posted Date
- 2009-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 448
- Registration Number
- NCT00286117
- Locations
- 🇮🇹
Research Site, Vicenza, Italy
Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2011-12-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9779
- Registration Number
- NCT00279448
- Locations
- 🇫🇷
Pfizer Investigational Site, Vannes, France
A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 51
- Registration Number
- NCT00241449
- Locations
- 🇬🇧
Research Site, York, United Kingdom
Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 180
- Registration Number
- NCT00233610
- Locations
- 🇮🇹
Research Site, Roma, Italy
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 317
- Registration Number
- NCT00229697
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.